Profound Medical Corp. (PRN.TO)
Profound Medical Corp. operates in the Medical - Devices industry of the Healthcare sector, headquartered in Mississauga, ON, CA. The stock last traded at $9.65, down 0.92% on the session, giving a market capitalisation of $350.7M. Its beta of 0.53 implies it has historically moved less than the broad market.
Profound Medical Corp., along with its subsidiaries, operates as a commercial-stage medical technology firm. The company specializes in creating magnetic resonance (MR) guided ablation therapies designed to address prostate conditions, uterine fibroids, and to provide palliative pain management. Its market reach extends to Canada, Germany, the United States, and Finland. The company's primary offering is the TULSA-PRO system, which is engineered to integrate with magnetic resonance imaging (MRI) scanners within hospitals and clinical treatment facilities. Additionally, Profound Medical offers Sonalleve, a versatile therapeutic platform that treats uterine fibroids, delivers palliative pain relief for bone metastases, and provides non-invasive solutions for uterine fibroid treatment. Profound Medical Corp. maintains its corporate headquarters in Mississauga, Canada.
Profound Medical Corp. is most often compared with the following Healthcare names: